镰状细胞病患者的静脉血栓栓塞症:叙述性综述。

IF 1.2 4区 医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
Hemoglobin Pub Date : 2024-07-01 Epub Date: 2024-10-18 DOI:10.1080/03630269.2024.2371884
Ismail A Raslan, Ziad Solh, Kevin H M Kuo, Jameel Abdulrehman
{"title":"镰状细胞病患者的静脉血栓栓塞症:叙述性综述。","authors":"Ismail A Raslan, Ziad Solh, Kevin H M Kuo, Jameel Abdulrehman","doi":"10.1080/03630269.2024.2371884","DOIUrl":null,"url":null,"abstract":"<p><p>Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by vaso-occlusion, hemolysis of red blood cells (RBC), and a predisposition for venous thromboembolism (VTE). The sickling and hemolysis of RBC culminate in coagulation system abnormalities, platelet activation, endothelial dysfunction, and impaired blood flow manifesting as a prothrombotic state. In addition, individuals with SCD are often exposed to extrinsic risk factors for VTE including recurrent hospitalizations, central venous catheters, and acute medical illnesses. The diagnosis is often challenging as symptoms may mimic other complications of SCD, and there is little data to guide diagnostic algorithms involving probability scoring in the SCD population. Non-anticoagulant strategies aimed at reducing disease severity may aid in lowering the risk of VTE, but data is limited. Furthermore, high quality evidence regarding anticoagulation in prevention and treatment of SCD is severely lacking, resulting in heterogeneity in clinical practice. In this narrative review we aim to review the prothrombotic pathophysiology of SCD, to describe the risk factors, high risk of mortality, and types of VTE in SCD, to develop an approach to the diagnosis of VTE in SCD, and to understand the limited available evidence for the prevention and treatment of VTE in SCD.</p>","PeriodicalId":12997,"journal":{"name":"Hemoglobin","volume":" ","pages":"231-243"},"PeriodicalIF":1.2000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Venous Thromboembolism in Individuals with Sickle Cell Disease: A Narrative Review.\",\"authors\":\"Ismail A Raslan, Ziad Solh, Kevin H M Kuo, Jameel Abdulrehman\",\"doi\":\"10.1080/03630269.2024.2371884\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by vaso-occlusion, hemolysis of red blood cells (RBC), and a predisposition for venous thromboembolism (VTE). The sickling and hemolysis of RBC culminate in coagulation system abnormalities, platelet activation, endothelial dysfunction, and impaired blood flow manifesting as a prothrombotic state. In addition, individuals with SCD are often exposed to extrinsic risk factors for VTE including recurrent hospitalizations, central venous catheters, and acute medical illnesses. The diagnosis is often challenging as symptoms may mimic other complications of SCD, and there is little data to guide diagnostic algorithms involving probability scoring in the SCD population. Non-anticoagulant strategies aimed at reducing disease severity may aid in lowering the risk of VTE, but data is limited. Furthermore, high quality evidence regarding anticoagulation in prevention and treatment of SCD is severely lacking, resulting in heterogeneity in clinical practice. In this narrative review we aim to review the prothrombotic pathophysiology of SCD, to describe the risk factors, high risk of mortality, and types of VTE in SCD, to develop an approach to the diagnosis of VTE in SCD, and to understand the limited available evidence for the prevention and treatment of VTE in SCD.</p>\",\"PeriodicalId\":12997,\"journal\":{\"name\":\"Hemoglobin\",\"volume\":\" \",\"pages\":\"231-243\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hemoglobin\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/03630269.2024.2371884\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hemoglobin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03630269.2024.2371884","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

镰状细胞病(SCD)是一种遗传性血红蛋白病,其特点是血管闭塞、红细胞(RBC)溶血以及易患静脉血栓栓塞症(VTE)。红细胞的镰状溶解和溶血最终导致凝血系统异常、血小板活化、内皮功能障碍和血流受阻,表现为血栓前状态。此外,SCD 患者经常面临 VTE 的外在危险因素,包括反复住院、中心静脉导管和急性内科疾病。由于症状可能与 SCD 的其他并发症相似,因此诊断往往具有挑战性,而且目前几乎没有数据可用于指导 SCD 群体中涉及概率评分的诊断算法。旨在降低疾病严重程度的非抗凝策略可能有助于降低 VTE 风险,但数据有限。此外,有关抗凝预防和治疗 SCD 的高质量证据严重缺乏,导致临床实践中的异质性。在这篇叙述性综述中,我们旨在回顾 SCD 的血栓前病理生理学,描述 SCD 中 VTE 的风险因素、高死亡率风险和类型,制定诊断 SCD 中 VTE 的方法,并了解预防和治疗 SCD 中 VTE 的有限可用证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Venous Thromboembolism in Individuals with Sickle Cell Disease: A Narrative Review.

Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by vaso-occlusion, hemolysis of red blood cells (RBC), and a predisposition for venous thromboembolism (VTE). The sickling and hemolysis of RBC culminate in coagulation system abnormalities, platelet activation, endothelial dysfunction, and impaired blood flow manifesting as a prothrombotic state. In addition, individuals with SCD are often exposed to extrinsic risk factors for VTE including recurrent hospitalizations, central venous catheters, and acute medical illnesses. The diagnosis is often challenging as symptoms may mimic other complications of SCD, and there is little data to guide diagnostic algorithms involving probability scoring in the SCD population. Non-anticoagulant strategies aimed at reducing disease severity may aid in lowering the risk of VTE, but data is limited. Furthermore, high quality evidence regarding anticoagulation in prevention and treatment of SCD is severely lacking, resulting in heterogeneity in clinical practice. In this narrative review we aim to review the prothrombotic pathophysiology of SCD, to describe the risk factors, high risk of mortality, and types of VTE in SCD, to develop an approach to the diagnosis of VTE in SCD, and to understand the limited available evidence for the prevention and treatment of VTE in SCD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hemoglobin
Hemoglobin 医学-生化与分子生物学
CiteScore
1.70
自引率
10.00%
发文量
59
审稿时长
3 months
期刊介绍: Hemoglobin is a journal in the English language for the communication of research and information concerning hemoglobin in humans and other species. Hemoglobin publishes articles, reviews, points of view The journal covers topics such as: structure, function, genetics and evolution of hemoglobins biochemical and biophysical properties of hemoglobin molecules characterization of hemoglobin disorders (variants and thalassemias), consequences and treatment of hemoglobin disorders epidemiology and prevention of hemoglobin disorders (neo-natal and adult screening) modulating factors methodology used for diagnosis of hemoglobin disorders
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信